Pyrazolopyrimidines as protein kinase inhibitors
    7.
    发明授权
    Pyrazolopyrimidines as protein kinase inhibitors 有权
    吡唑并嘧啶作为蛋白激酶抑制剂

    公开(公告)号:US07449488B2

    公开(公告)日:2008-11-11

    申请号:US11244628

    申请日:2005-10-06

    CPC分类号: C07D487/04

    摘要: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

    摘要翻译: 在其许多实施方案中,本发明提供了一类新颖的吡唑并[1,5-a]嘧啶化合物作为蛋白质和/或检查点激酶的抑制剂,制备此类化合物的方法,包含一种或多种这类化合物的药物组合物, 制备包括一种或多种这样的化合物的药物制剂,以及使用这些化合物或药物组合物治疗,预防,抑制或改善与蛋白质或检查点激酶相关的一种或多种疾病的方法。 本发明还涉及丙型肝炎病毒(HCV)复制的抑制。 特别地,本发明的实施方案提供了用于抑制HCV RNA依赖性RNA聚合酶酶活性的化合物和方法。 本发明还提供了预防和治疗HCV感染的组合物和方法。

    Imidazopyrazines as cyclin dependent kinase inhibitors
    8.
    发明授权
    Imidazopyrazines as cyclin dependent kinase inhibitors 失效
    咪唑吡嗪作为细胞周期蛋白依赖性激酶抑制剂

    公开(公告)号:US07186740B2

    公开(公告)日:2007-03-06

    申请号:US10666424

    申请日:2003-09-19

    CPC分类号: C07D487/04

    摘要: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a] pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

    摘要翻译: 在其许多实施方案中,本发明提供了一类新颖的咪唑并[1,2-a]吡嗪化合物作为细胞周期蛋白依赖性激酶的抑制剂,制备此类化合物的方法,含有一种或多种此类化合物的药物组合物,制备药物制剂的方法 包括一种或多种这样的化合物,以及使用这些化合物或药物组合物治疗,预防,抑制或改善与CDK相关的一种或多种疾病的方法。